George Soros and the team that manages Harvard University’s endowment recently made opposite bets on China Biologic Products Inc., a Beijing-based producer of human plasma products. Soros Fund Management LLC raised its stake in the second quarter to make the company its biggest equity holding based in mainland China, while Harvard Management Co. reduced its stake, according to separate regulatory filings in mid-August. Neither fund specified when the transactions were made, though the...